Table 2.

Treatment regime

	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5
INF-a dose	6 million IU 3 × weekly (s.c.)	3 million IU 3 × weekly (s.c.)	35 milion IU 20 × (i.v.) in 8 weeks/15 million IU 3× weekly (s.c.) for 13 weeks/ 10 milion IU 3 × weekly (s.c.) for 13 weeks*	30 milion IU 20 × (i.v.) in 4 weeks followed by 15 million IU 3× weekly (s.c.) for 35 weeks followd by 10 milion IU 3 × weekly (s.c.) for 12 weeks	30 milion IU 9 × (i.v.) in 2 weeks followed by 20 milion IU 11× (i.v.) in 3 weeks followed by 15 million IU 3× weekly (s.c.) for 13 weeks**
INF-α treatment period	2 years 9 months	7 months	8 months	12 months	4 months
Last date of INF-α treatment	March 2004	August 1998	July 2012	January 2012	June 2011
Disease free interval	4 months	5 years 6 months	6 months	3 months	2 months
Surgically excised metastases+	Yes	Yes	No	Yes	Yes
Interval between INF-α and ECT treatment	4 years 8 months	12 years 11 months	7 months	6 months	7 months
ECT treatment	November 2008	July 2011	February 2013	July 2013	January 2012
ECT drug	Cisplatin	Cisplatin	Bleomycin	Bleomycin	Bleomycin
Number of lesions	2	1	80	23	5
Size of the nodules	1.0 × 1.5 cm 1.5 × 1.5 cm	3 × 3 cm	0.3–1 cm	0.1–0.8 cm	0.7–1.5 cm
Effect after 4 weeks	CR	CR	> 85% CR	All CR	100% PR
LRD*** or date of death (D)	April 2010 (LRD)	December 2014 (LRD)	April 2014 (LRD)	December 2013 (D)	March 2013 (D)

^*prematurelly terminated treatment due to ineffective treatment;

^**intravenous dose (i.v. dose) was decreased to 20 million IU due to pathological liver tests - prematurelly terminated treatment due to side effects

⁺details on localization and number of excised metastates in paragraph Pacients’ caracteristics.

^***after last record date at the Institute of Oncology Ljubljana patients were given only paliative care at their regional centers

CR = complete response; ECT = electrochemotherapy; i.v. = intravenous; PR = partial response; s.c. = subcutaneously; s.c = subcutaneous;